CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 1 enrolled
Drug / intervention
StrataGraftbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05517902
NCT05517902Phase 3Completed

A Phase 3 Multicenter, Single-Arm, Open-Label Study Evaluating the Safety, Tolerability and Efficacy of StrataGraft® Construct in Pediatric Subjects With Deep Partial Thickness (DPT) Thermal Burns

Stratatech, a Mallinckrodt Company·interventional·Posted Aug 26, 2022·Updated Mar 18, 2025

In Brief

A Phase 3 clinical trial evaluating StrataGraft for Skin Wound and 2 related conditions. Completed, enrolled 1 participant across 1 site.

Detailed Summary

Autografting is a surgical procedure to transplant healthy skin (donor skin) from another part of the participant's own body (donor site) to the burned part. Autografting is the usual treatment for DPT burns. It works to close the wound, but can cause other problems: * Donor sites are painful, can become infected or scarred, or can even become full thickness (FT) wounds themselves * Treatment problems can require more grafting * Additional surgery increases the risk of medical problems caused by the treatment Stratatech is trying to find a safe and effective alternative to autografting to promote the healing of severe burns. The purpose of this study was to evaluate whether StrataGraft treatment eliminates or reduces the need for autografting and promotes wound closure in a pediatric population with thermal burns that contain intact dermal elements and for which autografting is clinically indicated (DPT burns). Participants were enrolled into one of two age-based cohorts: 2 to \< 12 years and 12 to ≤ 17 years to receive a single application of StrataGraft, in up to 3 non-contiguous DPT burn areas located on the same extremity or plane of the torso.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 3CompletedFinished
2023202420252026
First PostedAug 26, 2022
Enrollment StartApr 28, 2023
Primary CompletionMay 9, 2024
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 3.9 years ago

Interventions

StrataGraftbiological

StrataGraft® Construct